Results 171 to 180 of about 27,163 (253)

Fingolimod as a Neuroprotective Agent in Ischemic Stroke: A Review of Preclinical and Clinical Evidence. [PDF]

J Clin Med
Ciubotaru A, Covali R, Grosu C, Alexa D, Pilă EF, Cucu AI, Bobu AM, Sargu GD, Riscanu L, Tirnovanu MC, Adam C, Popa R, Filip C, Ignat EB.   +13 more
europepmc   +1 more source

Fingolimod potentiates the antifungal activity of fluconazole against fluconazole-resistant <i>Candida auris</i>. [PDF]

Front Cell Infect Microbiol
Bae JH, Eom YB.
europepmc   +1 more source

Treatment satisfaction significantly improves in patients with multiple sclerosis switching from interferon beta therapy to peginterferon beta-1a every 2 weeks [PDF]

, 2018
Dong, Qunming, Hendin, Barry, Huang, Deren, Jhaveri, Mehul, Jones, Daniel L, Livingston, Terrie, Naismith, Robert T, Watson, Crystal, Wray, Sibyl E   +8 more
core   +1 more source

Akute Uveitis Anterior bei einem mit Fingolimod (FTY720) behandelten Patienten mit multipler Sklerose [PDF]

, 2017
Heather G. Mack, Melissa Chih-Hui Tien, Owen White   +2 more
openalex   +1 more source

Fingolimod Improves Anxiety-like Behavior and Modulates Sphingosine-1-Phosphate Receptors Gene Expression in a Diabetic Mouse Model. [PDF]

Biomolecules
Wencel PL, Blecharz-Klin K, Piechal A, Pyrzanowska J, Mirowska-Guzel D, Strosznajder RP.   +5 more
europepmc   +1 more source

Differential effect of Fingolimod and Natalizumab treatments on B lymphocyte subpopulations and humoral responses in patients with relapsing remitting multiple sclerosis [PDF]

, 2014
Μπουλογιάννη, Ιουλία
core  

Safety of disease-modifying therapies in multiple sclerosis: real-world data from the Austrian MS Treatment Registry (AMSTR). [PDF]

J Neurol
Monschein T, Untersteiner H, Ponleitner M, Krajnc N, Zrzavy T, Bsteh G, Rommer P, Kornek B, Enzinger C, Di Pauli F, Kraus J, Guger M, Leutmezer F, Berger T, Austrian MS Treatment Registry (AMSTR).   +14 more
europepmc   +1 more source

Fingolimod-Associated Central Serous Retinopathy Presenting Eight Years after Treatment Initiation: a Case Report

Panos S. Gartaganis, Panagiotis Stavrakas, Evita Evangelia Christou, Marina Vasalaki, Efthymios Karmiris   +4 more
openalex   +1 more source

Biomarker discovery using NUcleic Acid-Linked Immuno-Sandwich Assay in multiple sclerosis patients experiencing progression independent of relapse activity. [PDF]

Mult Scler
Sandgren S, Maceski AM, Benkert P, Einsiedler M, Schaedelin S, Oechtering J, Achtnichts L, Lalive PH, Müller S, Pot C, Heslegrave A, Hunt D, Lycke J, Hoepner R, Roth P, Gobbi C, Comabella M, Derfuss T, Derfuss T, Kappos L, Granziera C, Abdelhak A, Leppert D, Willemse EA, Zetterberg H, Kuhle J.   +25 more
europepmc   +1 more source

Minimal association between Th1-specific responses to COVID-19 vaccines and SARS-CoV-2 breakthrough infections in multiple sclerosis patients receiving disease-modifying therapies. [PDF]

Front Immunol
Aiello A, Navarra A, Haggiag S, Ruggieri S, Cuzzi G, Vanini V, Salmi A, Notari S, Altera AMG, Meschi S, Colavita F, Cimini E, Tortorella C, Prosperini L, Quartuccio ME, Galgani S, Puro V, Maggi F, Grifoni A, Sette A, Nicastri E, Gasperini C, Goletti D.   +22 more
europepmc   +1 more source